Oncolytics Biotech Inc.

ONCY

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$0.8431

+US$0.0414 · +5.16%

8月21日 16:00 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

32/ 100

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

动量

Weakening

情绪

Mixed

风险韧性

High Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Jared Kelly
上市以来: 2001年10月5日
雇员: 29

市场位置

日内区间

当前US$0.8431，

US$0.80US$0.845

52周区间

当前US$0.8431，

US$0.73US$1.51

开盘价: US$0.80
前收盘价: US$0.8017
成交量: 54.5万; 0.43× 平均值
平均成交量: 128.06万; 日均成交量
市值: 8461.44万 USD
贝塔: 1.14; 市场参考 1
50天平均值: US$0.8542; 低于平均水平-1.30%
200天平均值: US$0.9436; 低于平均水平-10.65%

财务数据

财务报表

损益趋势

营业利润

−2872.5万 USD-12.46%

净利润

−2875.9万 USD-26.17%

项目（USD）	2025财年	2024财年	2023财年	2022财年	2021财年
研究与开发	1331.4万 USD	1544.3万 USD	1334.92万 USD	1137.05万 USD	1292万 USD
销售、一般及管理费用	1541.1万 USD	1009.9万 USD	1181.89万 USD	817.86万 USD	1286.3万 USD
营业费用	2872.5万 USD	2554.2万 USD	2547.19万 USD	1983.79万 USD	2623.49万 USD
利息收入	52.96万 USD	119.9万 USD	132.6万 USD	52.8万 USD	—
折旧和摊销	7万 USD	8.7万 USD	30.38万 USD	28.88万 USD	45.2万 USD
营业利润	−2872.5万 USD	−2554.2万 USD	−2547.19万 USD	−1983.79万 USD	−2623.49万 USD
净利润	−2875.9万 USD	−2279.4万 USD	−2091.96万 USD	−1829.87万 USD	−2630.4万 USD

公司数据更新于 2026年8月24日。

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

评级分布

10项评级

强力买入00%

买入880%

持有220%

卖出00%

强力卖出00%

ONCY 消息

globenewswire.com2026年8月18日

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free…

阅读源码

globenewswire.com2026年7月20日

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track…

阅读源码

globenewswire.com2026年7月13日

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational…

阅读源码

globenewswire.com2026年6月16日

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings planned…

阅读源码

globenewswire.com2026年6月2日

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy…

阅读源码

globenewswire.com2026年6月1日

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study…

阅读源码